BSEM
BioStem Technologies, Inc.
There isn't enough reported data to score BSEM yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BSEM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Strong |
BSEM's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BSEM PE Valuation
BSEM has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BSEM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect BSEM's losses to grow, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over BSEM on the outlook, with more favorable revenue and profitability expectations.
BSEM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -387% |
| Q2 2026 | -$1.68 | -251% |
| Q1 2026 | -$1.18 | -183% |
| Q4 2025 | -$0.49 | -134% |
| Q3 2025 | $0.82 | +34% |
| Q2 2025 | $1.11 | +247% |
| Q1 2025 | $1.43 | +$1.63 |
| Q4 2024 | $1.43 | +$1.94 |
BSEM has swung to a loss: it lost $2.35 per share over the past year, after a profit the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BSEM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -27% |
| Q2 2026 | $7.9M | -84% |
| Q1 2026 | $6.1M | -92% |
| Q3 2025 | $10.5M | -87% |
| Q2 2025 | $49.3M | -34% |
| Q1 2025 | $72.5M | +73% |
| Q4 2024 | $102.9M | +799% |
| Q3 2024 | $82.6M | +2194% |
BSEM's revenue has slid since its 2024 peak: $8M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -128% | -142 points |
| Q2 2026 | -106% | -107 points |
| Q1 2026 | -145% | -152 points |
| Q3 2025 | 14% | +2.6 points |
| Q2 2025 | 0.2% | -12 points |
| Q1 2025 | 7.2% | -3.8 points |
| Q4 2024 | 8.2% | +33 points |
| Q3 2024 | 11% | -3.5 points |
BSEM's operating margin was −128% last quarter, down 128 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BSEM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BSEM on profitability, with a higher operating margin.
BSEM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.8M | -$4M |
| Q1 2026 | -$827.3K | -121% |
| Q4 2025 | $2.4M | -70% |
| Q3 2025 | -$4.8M | -152% |
| Q2 2025 | $5.1M | -18% |
| Q1 2025 | $3.9M | +622% |
| Q4 2024 | $8M | +$9.4M |
| Q3 2024 | $9.3M | +$9.8M |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with BSEM at down 371%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
BSEM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +537K shares |
| 1 year | -23% | -5.4M shares |
| 3 years | +32% | +4.4M shares |
| 5 years | +93% | +8.6M shares |
| Available history | +94% | +8.7M shares |
BSEM has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.00 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BSEM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.6x | Net Cash |
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -0.2x | Net Cash |
| Q1 2024 | 19.3x | High |
BSEM has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BSEM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 3.2 | Oversold |
BSEM's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BSEM PE vs Healthcare Sector
| Metric | BSEM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BSEM has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BSEM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.07 | 37% below |
| 20 week MA | $3.08 | 58% below |
| 50 week MA | $4.09 | 68% below |
| 100 week MA | $7.27 | 82% below |
| 200 week MA | $6.91 | 81% below |
BSEM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BSEM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.50 | $1.40 | -44% |
| 2021 | $1.40 | $1.10 | -21% |
| 2022 | $1.10 | $3.48 | +216% |
| 2023 | $3.48 | $5.86 | +68% |
| 2024 | $5.86 | $12.7 | +116% |
| 2025 | $12.7 | $3.87 | -69% |
| 2026 YTD | $3.87 | $1.30 | -66% |
BSEM's yearly returns have swung widely, from +216% in 2022 to −69% in 2025. It's down 66% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BSEM on returns for 2026, with the stronger performance.